14
Participants
Start Date
December 31, 2009
Primary Completion Date
August 31, 2012
Study Completion Date
August 31, 2012
Lis-dexamphetamine
Eligible subjects will be dispensed open label LDX (VyvanseTM). All subjects will start at 20 mg once a day dose and will be titrated up weekly by 10 mg increments up to a maximum dose of 70 mg. If a subject experiences intolerable side effects at a particular dose, a step down to the next tolerated level is allowed.
Duke Child and Family Study Center, Durham
Lead Sponsor
Collaborators (1)
Shire
INDUSTRY
Duke University
OTHER